AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ...

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab ...

The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

A dark money anti-pharma bus —A rare disease treatment approval for Zevra —An FTC lawsuit against pharmacy benefit managers ...

patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial Survival results for AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...

AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...

It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...

AstraZeneca plc (AZN, AZN.L) announced on Monday that the high-level results from the TROPION-Breast01 Phase III trial of datopotamab ...